Alshehri Abdullah S, Algarni Abdullah M, Almahdi Hussein Ahmed M, Asiri Abdulkhaliq Hadi H, Asiri Hassan Yahya M, Alsulami Ahmad Abdullah H, Alasiri Hassan Ahmed A, Hassan Nawaf Khalid A
Department of Psychiatry, King Khalid University Medical City, Abha, Saudi Arabia.
Family Medicine Consultant, Aseer Central Hospital, Abha, Aseer Region, Saudi Arabia.
J Educ Health Promot. 2024 Jan 22;12:425. doi: 10.4103/jehp.jehp_809_23. eCollection 2023.
Depression is a common mental health disorder that affects millions of people worldwide. Globally, major depressive disorder (MDD) is a public health concern; nearly, it affects more than 300 million people. The coronavirus disease 2019 (COVID-19) pandemic lockdown, travel restrictions, social distancing, and COVID-19 vaccine acceptance have aggravated psychological disorders, such as depression and suicidal tendencies. Treatment-resistant depression (TRD) is typically defined as a lack of response to at least two different antidepressant medications or psychotherapies. TRD is common and has been associated with higher comorbidities and prolonged duration of illness, leading to a substantial medical and economic burden.
A cross-sectional study was designed to determine the epidemiology and estimate the prevalence of TRD in Abha City, Assir Region, Kingdom of Saudi Arabia. The study includes adult patients who were attended to the psychiatry department and aged 18-65 years diagnosed with major depressive depression. A total of 651 study participants were recruited.
Of the total 651 depressive disorder cases, 134 (20.6%) were reported as TRD and the remaining 517 (79.4%) were nontreatment-resistant depressive cases. Of the 651 depression participants, 176 (27%) were males and 475 (73%) were females. More than one-quarter (180 (28%)) had been associated with chronic morbidity. One-tenth of the depressive patients were suffering from thyroid disorders, followed by hypertension (10%), autoimmune diseases (10%), and diabetes mellitus (8%).
TRD emerged as a threat to public health and challenging psychiatric care providers, and further innovative techniques and effective newer drugs to treat depression need to be researched. The treatment complaint mechanism is warranted, encouraging people to get treatment from the psychiatrist by removing the stigma of mental illness, which is needed to improve the quality of life of TRD patients.
抑郁症是一种常见的心理健康障碍，影响着全球数百万人。在全球范围内，重度抑郁症（MDD）是一个公共卫生问题；几乎影响着超过3亿人。2019年冠状病毒病（COVID-19）大流行封锁、旅行限制、社交距离以及对COVID-19疫苗的接受情况加剧了抑郁症和自杀倾向等心理障碍。难治性抑郁症（TRD）通常定义为对至少两种不同的抗抑郁药物或心理治疗无反应。TRD很常见，并且与更高的合并症发生率和更长的病程相关，导致巨大的医疗和经济负担。
设计了一项横断面研究，以确定沙特阿拉伯王国阿西尔地区阿卜哈市TRD的流行病学情况并估计其患病率。该研究纳入了到精神科就诊、年龄在18 - 65岁且被诊断为重度抑郁症的成年患者。共招募了651名研究参与者。
在总共651例抑郁症病例中，134例（20.6%）被报告为难治性抑郁症，其余517例（79.4%）为非难治性抑郁症病例。在651名抑郁症参与者中，176名（27%）为男性，475名（73%）为女性。超过四分之一（180名（28%））与慢性疾病有关。十分之一的抑郁症患者患有甲状腺疾病，其次是高血压（10%）、自身免疫性疾病（10%）和糖尿病（8%）。
难治性抑郁症已成为对公共卫生的威胁，并给精神科护理人员带来挑战，需要进一步研究治疗抑郁症的创新技术和更有效的新药。治疗投诉机制是必要的，通过消除精神疾病的污名鼓励人们寻求精神科医生的治疗，这对于提高难治性抑郁症患者的生活质量是必要的。
